Bristol Myers Squibb and insitro Expand Collaboration to Develop New ALS Therapies

insitro and Bristol Myers Squibb expanded their collaboration to include two new ALS treatment targets discovered via insitro's AI-driven Virtual Human platform. The joint effort aims to identify key biological drivers for disease-modifying interventions. insitro received a $10 million milestone payment and will advance its own oligonucleotide program for ALS-1 while progressing a small molecule program for BMS for ALS-1.